Oncolytics up 12% premarket on modest volume

Shares of Oncolytics Biotech (ONCY) are poised for a gap up this morning in response to positive Phase 2 clinical trial results for REOLYSIN.

The 165-patient study REO 018 compared the use of REOLYSIN in combination with carboplatin and paclitaxel for the treatment of patients with second-line platinum-refractory taxane-naive head and neck cancers with carboplatin, paclitaxel and placebo.

In the intent-to-treat analysis of 118 loco-regional patients, the REOLYSIN group showed a statically significant improvement in OS and PFS.

Comments (1)
  • pat45
    , contributor
    Comments (470) | Send Message
    Looks interesting will watch ONCY for when biotechnology back in favor.
    8 Apr 2014, 01:27 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs